Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults With Phenylketonuria (PKU)

NCT07694440 is registered in ClinicalTrials.gov with Maze Therapeutics as lead sponsor.

NCT NCT07694440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07694440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults With Phenylketonuria (PKU)
Lead sponsor
Maze Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 23, 2026
Completion date
February 29, 2028
Enrollment
38 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria (pku)